Open-label, randomized, crossover clinical trials for single oral dose of 60mg fimasartan and single IV infusion of 30mg fimasartan to evaluate the absolute bioavailability of Kanarb® tablet (fimasartan) in healthy subjects

Inclusion Criteria:

• age: 20 - 55 years
• body weight: standard weight(Broca's index, Possible range is plus or minus 20percent)
• written informed consent

Exclusion Criteria:

• known allergy to Fimasartan
• existing cardiac or hematological diseases
• existing hepatic and renal diseases
• existing gastrointestinal diseases
• acute or chronic diseases which could affect drug absorption or metabolism history of any serious psychological disorder
• abnormal diet which could affect drug absorption or metabolism
• positive drug or alcohol screening
• smokers of 10 or more cigarettes per day
• participation in a clinical trial during the last 90 days prior to the start of the study